Patient Reported Outcomes from Pharmacist-Led Multiple Sclerosis Assessments in a Specialty Pharmacy Setting
Background: Disease-modifying therapy (DMT) has demonstrated benefits for patients in reducing relapse rates, disability progression, and...
Continued Expansion of a Multiple Sclerosis Pharmacy Program
Background: Kaiser Permanente Washington (KPWA) launched a Multiple Sclerosis (MS) Pharmacy Program in June 2014 to support patients on...
Altered Expression of the RNA Binding Protein Heterogeneous Nuclear Ribonucleoprotein A1 (A1) Contributes to the Pathogenesis of Neurodegeneration in Multiple Sclerosis
Background: Dysfunctional RNA binding proteins (RBPs) have been shown to contribute to the pathogenesis of neurodegeneration (NDG) in...
Oligoclonal Band Negative Multiple Sclerosis in Puerto Rico
Background: The incidence of multiple sclerosis (MS) in Puerto Rico (PR) is higher than in other Latin American and Caribbean countries....
The Influence of Tethered and Joint HCP and Patient Education on Clinical Practice Behavior, Patient Activation, and Empowerment
Background: Advances in disease-modifying therapies (DMT) for multiple sclerosis (MS) have left clinicians challenged to incorporate DMTs,...
Longitudinal Olfactory Patterns in Multiple Sclerosis: A Scoping Review and Implications for Use in Management of Disease
Background: Previous studies reviewing the presence of olfactory dysfunction (OD) in Multiple Sclerosis (MS) have focused on the prevalence...